Sandrine Jayne

Featured in: Favicon

Articles

The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion

Oct 15, 2024 | onlinelibrary.wiley.com | Sandrine Jayne |Cristina Lopez |Cristina Conde López |Christian-Albrechts-University Kiel |Natalie Put

INTRODUCTION Unlike other lymphoid malignancies, balanced, reciprocal chromosomal translocations are rare in chronic lymphocytic leukaemia (CLL).1 However, chromosomal translocation t(1;6)(p35.3;p25.2) has been previously described as a rare but recurrent event.2-5 The presence of this translocation in 12 previously reported cases of CLL has been associated with high-risk chromosomal aberrations like del(11q) and del(17p), unmutated IGHV status and a progressive clinical course (for review,...
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.

Dec 18, 2023 | biorxiv.org | Raji E. Joseph |Thomas E. Wales |Sandrine Jayne |Robert Britton

AbstractInhibition of Bruton tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders and multiple sclerosis. Since the approval of the first BTK inhibitor (BTKi), Ibrutinib, several other inhibitors including Acalabrutinib, Zanubrutinib, Tirabrutinib and Pirtobrutinib have been clinically approved.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.